Memorial Hospital Research Laboratories

The Jonathan Peled Lab


Jonathan Peled
Jonathan Peled, MD, PhD

Assistant Professor

Cancer immunotherapy hold tremendous promise, but durable responses in most disease types are achieved in only a minority of patients. For example, allogeneic hematopoietic-cell transplantation (allo-HCT) is a curative treatment for hematological malignancies, but its success is limited by relapse, graft-vs-host disease (GVHD), or infection. We and others have established that GVHD severity and mortality risk after transplantation are in part dependent on the composition of the intestinal microbiota, yet the mechanisms by which this is mediated remain poorly understood. The Peled laboratory seeks to use human specimens and mouse models to understand how the gut microbiome and host immunity regulate one another and how these relationships might be manipulated to improve immunotherapy for patients with cancer.

View the Peled Lab

Research Projects

Publications Highlights

Elkrief A, Waters NR, Smith N, Dai A, Slingerland J, Aleynick N, Febles B, Gogia P, Socci ND, Lumish M, Giardina PA, Chaft JE, Eng J, Motzer RJ, Mendelsohn RB, Markey KA, Zhuang M, Li Y, Yang Z, Hollmann TJ, Rudin CM, van den Brink MRM, Shia J, DeWolf S, Schoenfeld AJ, Hellmann MD, Babady NE, Faleck DM, Peled JU. Immune-Related Colitis Is Associated with Fecal Microbial Dysbiosis and Can Be Mitigated by Fecal Microbiota Transplantation. Cancer Immunol Res. 2024 Mar 4;12(3):308-321. doi: 10.1158/2326-6066.CIR-23-0498. PubMed PMID: 38108398; PubMed Central PMCID: PMC10932930.

Blair LM, Akhund-Zade J, Katsamakis ZA, Smibert OC, Wolfe AE, Giardina P, Slingerland J, Bercovici S, Perales MA, Taur Y, van den Brink MRM, Peled JU, Markey KA. Circulating microbial cell-free DNA is increased during neutropenia after hematopoietic stem cell transplantation. Blood Adv. 2023 Nov 14;7(21):6744-6750. doi: 10.1182/bloodadvances.2023010208. PubMed PMID: 37399491; PubMed Central PMCID: PMC10651422.

DeWolf S, Elhanati Y, Nichols K, Waters NR, Nguyen CL, Slingerland JB, Rodriguez N, Lyudovyk O, Giardina PA, Kousa AI, Andrlová H, Ceglia N, Fei T, Kappagantula R, Li Y, Aleynick N, Baez P, Murali R, Hayashi A, Lee N, Gipson B, Rangesa M, Katsamakis Z, Dai A, Blouin AG, Arcila M, Masilionis I, Chaligne R, Ponce DM, Landau HJ, Politikos I, Tamari R, Hanash AM, Jenq RR, Giralt SA, Markey KA, Zhang Y, Perales MA, Socci ND, Greenbaum BD, Iacobuzio-Donahue CA, Hollmann TJ, van den Brink MRM, Peled JUTissue-specific features of the T cell repertoire after allogeneic hematopoietic cell transplantation in human and mouse. Sci Transl Med. 2023 Jul 26;15(706):eabq0476. doi: 10.1126/scitranslmed.abq0476. Epub 2023 Jul 26. PubMed PMID: 37494469; PubMed Central PMCID: PMC10758167.

Ponce DM, Alousi AM, Nakamura R, Slingerland J, Calafiore M, Sandhu KS, Barker JN, Devlin S, Shia J, Giralt S, Perales MA, Moore G, Fatmi S, Soto C, Gomes A, Giardina P, Marcello L, Yan X, Tang T, Dreyer K, Chen J, Daley WL, Peled JU, van den Brink MRM, Hanash AM. A phase 2 study of interleukin-22 and systemic corticosteroids as initial treatment for acute GVHD of the lower GI tract. Blood. 2023 Mar 23;141(12):1389-1401. doi: 10.1182/blood.2021015111. PubMed PMID: 36399701; PubMed Central PMCID: PMC10163318.

Shouval R, Waters NR, Gomes ALC, Zuanelli Brambilla C, Fei T, Devlin SM, Nguyen CL, Markey KA, Dai A, Slingerland JB, Clurman AG, Fontana E, Amoretti LA, Wright RJ, Hohl TM, Taur Y, Sung AD, Weber D, Hashimoto D, Teshima T, Chao NJ, Holler E, Scordo M, Giralt SA, Perales MA, Peled JU, van den Brink MRM. Conditioning Regimens are Associated with Distinct Patterns of Microbiota Injury in Allogeneic Hematopoietic Cell Transplantation. Clin Cancer Res. 2023 Jan 4;29(1):165-173. doi: 10.1158/1078-0432.CCR-22-1254. PubMed PMID: 36322005; PubMed Central PMCID: PMC9812902.

View All Publications


Jonathan Peled

Jonathan Peled, MD, PhD


Assistant Professor

  • The Peled lab focuses on cancer immunotherapy.
  • MD, PhD, Albert Einstein College of Medicine
[email protected]
Email Address
View physician profile
Physician profile


Annamaria Ballweg

Research Fellow

Cindy Junes

Administrative Assistant

LeeAnn Marcello

Graduate Research Assistant

Elisha (Eli) Pinker

Research Technician

Madhumitha Rangesa

Research Assistant

Sukanya Sahu

Postdoctoral Fellow

Lab Affiliations


  • NHLBI K08
  • New Investigator Award from the American Society for Transplantation and Cellular Therapy
  • Career Development Award from the Parker Institute for Cancer Immunotherapy

Open Positions

To learn more about available postdoctoral opportunities, please visit our Career Center

To learn more about compensation and benefits for postdoctoral researchers at MSK, please visit Resources for Postdocs

Computational Biologist

Apply now

Postdoctoral Researcher

Apply now

Get in Touch


Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Jonathan Peled discloses the following relationships and financial interests:

  • CSL Behring
    Professional Services and Activities
  • Fred Hutchinson Cancer Research Center
    Professional Services and Activities
  • French National Research Agency
    Professional Services and Activities
  • Keio University
    Professional Services and Activities
  • MaaT Pharma
    Professional Services and Activities
  • Postbiotics Plus Research, LLC
    Equity; Professional Services and Activities (Uncompensated)
  • Seres Therapeutics
    Intellectual Property Rights
  • Tufts Medical Center
    Professional Services and Activities
  • Westchester Medical Center
    Professional Services and Activities

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2022 through disclosure submission in spring 2023). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].

View all disclosures